Home
  >  
Section 57
  >  
Chapter 56,707

Tumoral fibrosis effect on the radiation absorbed dose of (177) Lu-Tyr (3) -octreotate and (177) Lu-Tyr (3) -octreotate conjugated to gold nanoparticles

Azorín-Vega, E.P.; Zambrano-Ramírez, O.D.; Rojas-Calderón, E.L.; Ocampo-García, B.E.; Ferro-Flores, G.

Applied Radiation and Isotopes: Including Data Instrumentation and Methods for use in Agriculture Industry and Medicine 100: 96-100

2015

ISSN/ISBN: 0969-8043
PMID: 25305748
DOI: 10.1016/j.apradiso.2014.09.005
Accession: 056706500
The aim of this work was to evaluate the tumoral fibrosis effect on the radiation absorbed dose of the radiopharmaceuticals (177)Lu-Tyr(3)-octreotate (monomeric) and (177)Lu-Tyr(3)-octreotate-gold nanoparticles (multimeric) using an experimental HeLa cells tumoral model and the Monte Carlo PENELOPE code. Experimental and computer micro-environment models with or without fibrosis were constructed. Results showed that fibrosis increases up to 33% the tumor radiation absorbed dose, although the major effect on the dose was produced by the type of radiopharmaceutical (112Gy-multimeric vs. 43Gy-monomeric).

PDF emailed within 0-6 h: $19.90




Related References

Behera, A.; Banerjee, I.; De, K.; Munda, R.N.; Chattopadhayay, S.; Samanta, A.; Sarkar, B.; Ganguly, S.; Misra, M. 2013: Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of (99m)Tc-HYNIC-His(3)-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors Amino Acids 44(3): 933-946
Lewis, J.S.; Lewis, M.R.; Laforest, R.; Schwarz, S.W.; Srinivasan, A.; Schmidt, M.A.; Morris, M.M.; Wang, J.; Erion, J.L.; Bugaj, J.E.; Anderson, C.J. 1999: Human absorbed dose estimates of 90Y-DOTA-Y3-octreotate based on rat biodistribution data Journal of Labelled Compounds and Radiopharmaceuticals 42(Suppl 1): S729-S731
Ezziddin, S.; Lohmar, J.; Yong-Hing, C.J.; Sabet, A.; Ahmadzadehfar, H.; Kukuk, G.; Biersack, H.-J.ür.; Guhlke, S.; Reichmann, K. 2012: Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clinical Nuclear Medicine 37(6): E141-E147
Ma, M.T.; Cullinane, C.; Waldeck, K.; Roselt, P.; Hicks, R.J.; Blower, P.J. 2015: Rapid kit-based (68)Ga-labelling and PET imaging with THP-Tyr(3)-octreotate: a preliminary comparison with DOTA-Tyr(3)-octreotate Ejnmmi Research 5(1): 52
Larsson, M.; Bernhardt, P.; Svensson, J.B.; Wängberg, B.; Ahlman, H.åk.; Forssell-Aronsson, E. 2012: Estimation of absorbed dose to the kidneys in patients after treatment with 177Lu-octreotate: comparison between methods based on planar scintigraphy Ejnmmi Research 2(1): 49
Swärd, C.; Bernhardt, P.; Ahlman, H.åk.; Wängberg, B.; Forssell-Aronsson, E.; Larsson, M.; Svensson, J.; Rossi-Norrlund, R.; Kölby, L. 2010: 177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney World Journal of Surgery 34(6): 1368-1372
Petrik, M.; Laznickova, A.; Laznicek, M.; Zalutsky, M.R. 2007: Radiolabelling of glucose-Tyr3-octreotate with 125i and analysis of its metabolism in rats: comparison with radiolabelled DOTA-Tyr3-octreotate Anticancer Research 27(6b): 3941-3946
Kong, G.; Callahan, J.; Hofman, M.S.; Pattison, D.A.; Akhurst, T.; Michael, M.; Eu, P.; Hicks, R.J. 2017: High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours European Journal of Nuclear Medicine and Molecular Imaging 44(3): 476-489
Lobachevsky, P.; Smith, J.; Denoyer, D.; Skene, C.; White, J.; Flynn, B.L.; Kerr, D.J.; Hicks, R.J.; Martin, R.F. 2012: Tumour targeting of Auger emitters using DNA ligands conjugated to octreotate International Journal of Radiation Biology 88(12): 1009-1018
Balkin, E.R.; Liu, D.; Jia, F.; Ruthengael, V.C.; Shaffer, S.M.; Miller, W.H.; Lewis, M.R. 2014: Comparative biodistributions and dosimetry of [¹⁷⁷Lu]DOTA-anti-bcl-2-PNA-Tyr³-octreotate and [¹⁷⁷Lu]DOTA-Tyr³-octreotate in a mouse model of B-cell lymphoma/leukemia Nuclear Medicine and Biology 41(1): 36-42
Mier, W.; Eritja, R.; Mohammed, A.; Haberkorn, U.; Eisenhut, M. 2001: Synthesis and labeling of peptide nucleic acid oligomers conjugated to octreotate Journal of Labelled Compounds and Radiopharmaceuticals 44(Suppl 1): S954-S956
Melis, M.; Bijster, M.; de Visser, M.; Konijnenberg, M.W.; de Swart, J.; Rolleman, E.J.; Boerman, O.C.; Krenning, E.P.; de Jong, M. 2009: Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours European Journal of Nuclear Medicine and Molecular Imaging 36(12): 1968-1976
Violet, J.A.; Farrugia, G.; Skene, C.; White, J.; Lobachevsky, P.; Martin, R. 2016: Triple targeting of Auger emitters using octreotate conjugated to a DNA-binding ligand and a nuclear localizing signal International Journal of Radiation Biology 92(11): 707-715
Betzel, T.; Hess, T.; Waser, B.; Reubi, J.-C.; Roesch, F. 2008: Closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT Bioconjugate Chemistry 19(9): 1796-1802
Ezziddin, S.; Reichmann, K.; Yong-Hing, C.; Damm, M.; Risse, J.; Ahmadzadehfar, H.; Logvinski, T.; Guhlke, S.; Biersack, H.-J.; Sabet, A. 2013: Early prediction of tumour response to PRRT. the sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate NUKLEARMEDIZIN. Nuclear Medicine 52(5): 170-177